Long noncoding RNAs (lncRNAs) are emerging as key regulators in cancer initiation and progression. TP53TG1 is a recently identified lncRNA and several studies have shown that TP53TG1 may play the role of tumor suppressor gene or oncogene in different tumors. Nevertheless, the involvement of TP53TG1 in carcinogenesis of pancreatic ductal adenocarcinoma (PDAC) has not been characterized. In our studies, we identified that TP53TG1 was highly expressed in PDAC and was a novel regulator of PDAC development. Knockdown of TP53TG1 inhibited proliferation, induced apoptosis, and decreased migration and invasion in PDAC cells, whereas enhanced expression of TP53TG1 had the opposite effects. Mechanistically, TP53TG1 could directly bind to microRNA (miR)-96 and effectively function as a sponge for miR-96, thus antagonizing the functions of miR-96 and leading to derepression of its endogenous target KRAS, which is a core oncogene in the initiation and maintenance of PDAC. Taken together, these observations imply that TP53TG1 contributes to the growth and progression of PDAC by acting as a competing endogenous RNA (ceRNA) to competitively bind to miR-96 and regulate KRAS expression, which highlights the importance of the complicated miRNA-lncRNA network in modulating the progression of PDAC.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with a dismal 8% 5-year survival rate and is currently the third leading cause of cancer-related death in the USA.
In contrast to the steady increase in survival for most cancers in recent decades, disease-specific survival has only improved marginally for PDAC. 1, 2 The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. It is of paramount importance to understand the underlying pathogenesis and molecular alterations causing PDAC in order to develop novel diagnostic biomarkers and effective therapeutic strategies and improve the prognosis of PDAC.
Development of high-throughput transcriptome analyses and genome-wide surveys have shown that >90% of the total mammalian genome can be transcribed into various short or long noncoding RNAs (lncRNAs). 3, 4 MicroRNAs (miRNAs), a class of short noncoding (nc)RNA molecules that range in size from 19 to 25 nucleotides, regulate the expression of protein-coding genes by targeting mRNAs, leading to translational inhibition or RNA degradation. 5 LncRNAs are transcripts that are longer than 200 nucleotides in length and do not encode protein. 6 Although only a small portion of lncRNAs have been characterized in detail, many lncRNAs have emerged as regulators of various biological processes, such as epigenetic regulation, alternative splicing, RNA decay, cell cycle control, and cell fate determination. [7] [8] [9] Furthermore, multiple lines of evidence suggest that the abnormal expression of lncRNAs is associated with the development of diverse human diseases, and specific lncRNAs have also been shown to play a critical role in tumor initiation and progression, including PDAC. [10] [11] [12] [13] For example, LINC00673 is able to promote protein tyrosine phosphatase PTPN11 degradation through ubiquitination, resulting in decreased proliferation of pancreatic cancer cells. 14 Another characterized lncRNA, lincRNA-ROR, acts as an important regulator of ZEB1, promotes invasion and metastasis in pancreatic cancer, and may represent a novel therapeutic target. 15 LncRNA ENST00000480739 suppresses PDAC cell invasion by regulating osteosarcoma amplified-9 (OS-9)
and hypoxia-inducible factor-1α (HIF-1α). 16 Our previous studies have also shown that lncRNA MIR31HG is upregulated in PDAC and shows oncogenic property in PDAC development. 17 Recently, a new regulatory mechanism has been reported in which crosstalk between lncRNAs and mRNAs occurs by competing for shared miRNAs response elements. In this case, lncRNAs could interact with specific miRNAs and function as competing endogenous RNAs (ceRNA) to prevent targeted transcripts of these miRNAs from being degraded. An example of this type of regulation is exemplified by lncRNA MIR31HG, which binds miR-193b and regulates the expression level of its downstream miRNA-target genes in PDAC. 17 Similarly, lncRNA HOTAIR may function as a ceRNA to regulate HER2 expression through competition for miR-331-3p, thus playing an oncogenic role in gastric pathogenesis. 18 Other studies also showed that ceRNAs were involved in the tumorigenesis of multiple cancer types, including prostate, breast, liver and lung cancers and so on. [19] [20] [21] [22] Although ceRNA research is still in its initial stages, exploration of ceRNA interplay in cancer will provide new insight into mechanisms underlying the pathogenesis of cancers. 24 However, as in glioma, the expression of TP53TG1 was significantly upregulated, and overexpression of TP53TG1 promoted cell proliferation and migration but inhibited cell apoptosis under glucose deprivation. 25 TP53TG1 was also highly expressed in nasopharyngeal carcinoma and functionally promoted nasopharyngeal carcinoma malignant phenotypes. 26 Although several studies showed that TP53TG1 may play the role of tumor suppressor gene or oncogene in different tumors, the involvement of TP53TG1 in tumorigenesis of PDAC remains poorly understood.
In the present study, we identified that TP53TG1 was significantly upregulated in PDAC tissues compared with paired adjacent tissues.
After downregulating TP53TG1, the proliferation and invasion of PDAC cells were significantly inhibited, whereas upregulation of TP53TG1 had the opposite effects. Dual-luciferase reporter assay validated that TP53TG1 and 3′UTR of KRAS mRNA competitively bind with miR-96.
Our data further indicate that TP53TG1 could effectively function as a sponge for miR-96 to modulate the derepression of KRAS.
| MATERIAL S AND ME THODS

| Cell culture and tissue collection
The PDAC cell lines PANC-1 and MIA PaCa-2 were purchased from ATCC. BxPC-3 cells were kindly provided by Cell Bank, Chinese 
| Rapid amplification of cDNA ends
The rapid amplification of cDNA ends (RACE) program was carried out using Smarter RACE cDNA Amplification kit (Clontech, Mountain
View, CA, USA). Gene-specific primers for 5′-RACE (GSP1), 3′-RACE (GSP2), and each nested PCR NGSP1 and NGSP2 were designed in accordance with the NCBI sequence (NR_015381.1) and are listed in Table 1 . RACE PCR products were separated on a 1% agarose gel.
Individual bands were gel purified and cloned into PGEM-T vector (Promega, Madison, WI, USA) for sequencing.
| RNA extraction and RT-qPCR detection
Human PDAC cell and tissue RNA was extracted using TRIzol reagents (Invitrogen, Carlsbad, CA, USA). Total RNA was reverse transcribed to cDNA using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). cDNA was then diluted for RT-qPCR analysis using THUNDERBIRD SYBR qPCR mix (Toyobo) with specific primers. All reactions were run on Step One Plus Real Time PCR System (Applied Biosystems, Foster City, CA, USA). Primers used for RT-qPCR analysis are listed in Table 2 .
| siRNA and miRNA transfection
For RNA interference (RNAi)-mediated knockdown of TP53TG1, two different siRNAs were generated by GenePharma (Suzhou, Jiangsu, China). miRNA mimics were also synthesized and purified by GenePharma. Cells were transfected with 20 nmol/L siRNAs or 50 nmol/L miRNA mimics using the Lipofectamine RNAiMAX Reagent (Invitrogen). Sequences of the RNA used in transfections are described in Table 3 .
| Plasmid construction and transfection
The full length of TP53TG1 was synthesized and subcloned into the was used for plasmid transfection.
| Cell proliferation, apoptosis, migration and invasion analysis
Cell viability was measured using CCK-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) and the Cell-Light EdU Apollo were used to measure the anchorage-independent growth ability.
| In situ hybridization
RNA probes were prepared for in situ hybridization assays using the DIG RNA Labeling Kit (Roche, Basel, Switzerland). A digoxigenin-UTP labeled antisense RNA probe was derived from 183 to 607nt
of TP53TG1 for detecting TP53TG1 in PDAC cells. The digoxigenin-UTP labeled sense RNA probe derived from nucleotides 183 to 607 of TP53TG1 was used as a negative control.
| Cell cytoplasm/nucleus fraction isolation
Separation of nuclear and cytosolic fractions was done using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher
Scientific, Waltham, MA, USA). RNAs were extracted from each fraction using TRIzol reagent (Invitrogen) and subjected to RT-qPCR analysis.
| Dual luciferase reporter assay
Luciferase reporter assays were carried out using the Dual-Luciferase
Reporter Assay System (Promega). PmirGLO-TP53TG1 or pmirGLO-KRAS plasmids were cotransfected with miR-96 mimic into PANC-1 cells by using Lipofectamine 2000 (Invitrogen). Relative luciferase activity was normalized to Renilla luciferase activity 24 hours after transfection.
| RNA binding protein immunoprecipitation assay
RNA binding protein immunoprecipitation (RIP) experiments
were carried out using the Magna RIP RNA-Binding Protein
Immunoprecipitation Kit (Millipore, Burlington, MA, USA) according to the manufacturer's protocol. The Ago2 antibody used in RIP assays was obtained from Abcam (Cambridge, UK). Purified RNA was subjected to RT-qPCR to determine the presence of the binding targets using gene-specific primers.
| Western blot analysis
Cells were harvested and lysed in RIPA buffer (Pierce Biotechnology, TA B L E 1 Primers for rapid amplification of cDNA ends (RACE)
| Statistical analysis
Two-tailed Student's t-tests and one-way ANOVAs were used to analyze data with SPSS 22.0 software (IBM). Each experiment was carried out at least three times. Results of experiments are shown as mean ± SE. P-values <.05 were considered to be statistically significant.
| RE SULTS
| TP53TG1 is upregulated in PDAC
A 5′-and 3′-RACE analysis was carried out to determine the fulllength transcript of TP53TG1 ( Figure S1 ). As presented in the genome browser view of Figure 1A , TP53TG1 is a 694-bp transcript present on chr7 (q21,12), and contains three exons and a poly-A tail.
Compared with the NCBI sequence (NR_015381.1), the RACE data showed that there are 12 more bases at the 5′ ends of TP53TG1
( Figure 1B ). To confirm that TP53TG1 is indeed a noncoding RNA, we assessed the protein-coding potential of TP53TG1 using the CodingPotential Assessment Tool (CPAT, https://lilab.research.bcm.edu/ cpat/index), 27 which showed that the coding probability of TP53TG1 is very low (P < .05) and TP53TG1 has no coding label (Table 4) .
Data mining of publicly available gene profiling analysis results (GSE16515 and GSE15471) showed that TP53TG1 was expressed at higher levels in PDAC tissues than in nontumor pancreatic tissues ( Figure 1C ). To further validate this result, RT-qPCR analysis was done to determine the expression level of TP53TG1 in 15 paired PDAC and adjacent pancreatic tissue samples, and the results also showed that TP53TG1 is significantly upregulated in PDAC tumor tissues ( Figure 1D ).
| siRNA-mediated knockdown of TP53TG1 inhibits PDAC cell proliferation and invasion
We then tested whether TP53TG1 was functionally involved in PDAC tumorigenesis. For this purpose, we developed a TP53TG1 
TA B L E 2 Primers for RT-qPCR
Name Nucleotide sequence Wound-healing assays showed that TP53TG1 downregulation caused a marked reduction of cell migration during closure of an artificial wound created in a confluent cell monolayer ( Figure 3A) . The assay was carried out in the presence of mitomycin C to block cell proliferation. Using Transwell experiments, we determined the invasion ability of PDAC cells following treatment with siTP53TG1.
Upon downregulation of TP53TG1, the invasive abilities of PANC-1 and MIA PaCa-2 cells were significantly decreased ( Figure 3B ).
Furthermore, soft agar colony formation assays revealed that TP53TG1 knockdown cells showed significantly decreased anchorage-independent growth compared with the control group in PANC-1 and MIA PaCa-2 cells, as they displayed fewer and smaller colonies formed in soft agar ( Figure 3C ). Overall, it was concluded that TP53TG1 might have important roles in PDAC development and progression.
| Upregulation of TP53TG1 promotes PDAC cell proliferation and invasion
To further investigate the biological significance of TP53TG1 in PDAC, we carried out gain-of-function studies in PDAC cells 
| TP53TG1 is negatively regulated by miR-96
Recent studies have shown that lncRNAs may function through binding specific miRNAs. To examine whether TP53TG1 has a similar mechanism, we used DIANA-LncBase and miRcode to invest TP53TG1-miRNA interactions, 28, 29 and several miRNAs were predicted to be bound to TP53TG1 with high scores. We transfected PDAC cells with mimics of these miRNAs, and miR-96, a tumor suppressor gene in various types of cancer, 30, 31 was chosen for further studies given its most significant effect on TP53TG1 expression ( Figure S2 ). The predicted binding sites of miR-96 to the TP53TG1 sequence are illustrated in Figure 5A . RT-qPCR showed that overexpression of miR-96 significantly reduced TP53TG1 expression (>50%) in PANC-1 and MIA PaCa-2 cell lines ( Figure 5B ), F I G U R E 3 Downregulation of TP53TG1 inhibits pancreatic ductal adenocarcinoma (PDAC) cell migration and invasion. A, Wound-healing assays were carried out to determine the migratory ability of si-TP53TG1-transfected PANC-1 and MIA PaCa-2 cells. **P < .01, ***P < .001. B, Effect of TP53TG1 downregulation on the invasive abilities of PANC-1 and MIA PaCa-2 cells was measured using Transwell assays. ***P < .001. C, Colony formation assays were carried out to determine the anchorage-independent growth abilities of PANC-1 and MIA PaCa-2 cells after TP53TG1 knockdown. **P < .001. NC, negative control
showing the negative regulation of TP53TG1 by miR-96. Next, we examined the cellular localization of TP53TG1 in PDAC cell lines by in situ hybridization and the result showed that the majority of TP53TG1 signal was located in the cell cytoplasm, while a small amount of punctate staining was detected in the nucleus.
Reduction of in situ hybridization signal was observed in PDAC cells transfected with TP53TG1-targeted siRNA, which supported that the probe was specifically detecting the TP53TG1 transcript ( Figure 5C ). Moreover, TP53TG1 and miR-96 expression in nuclear and cytosolic fractions from PANC-1 and MIA PaCa-2 cells were measured by RT-qPCR. Differential enrichments of GAPDH and MALAT1 RNA were used as fractionation indicators. We observed a considerable increase in TP53TG1 and miR-96 expression in the cytoplasm versus the nucleus ( Figure 5D ), thus further confirming that TP53TG1 and miR-96 were both mainly localized in the cytoplasm. This provided a prerequisite for reciprocal interaction between TP53TG1 and miR-96.
| miR-96 competitively binds to TP53TG1 and KRAS
Our previous study showed that miR-96 functions as a tumor-suppressing miRNA in PDAC and directly targets the KRAS oncogene. 31 According to the prediction results, there are putative conserved binding sites for miR-96 on both TP53TG1 and the 3′UTR of KRAS mRNA ( Figure 6A ). To test whether miR-96 directly binds to TP53TG1
F I G U R E 4 Enforced expression of TP53TG1 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma (PDAC) cells.
A, TP53TG1 expression in PANC-1 and MIA PaCa-2 cells transfected with pcDNA3.1-TP53TG1 or empty pcDNA3.1 vector was measured by RT-qPCR. ***P < .001. B, CCK-8 assay was carried out to determine the growth curves of PANC-1 and MIA PaCa-2 cells after transfection with pcDNA3.1-TP53TG1 or empty pcDNA3.1 vector. **P < .01, ***P < .001. C, Proliferation in PANC-1 and MIA PaCa-2 cells after TP53TG1 overexpression was detected through EdU-incorporation assays. Proliferating cells were labeled with EdU. Scale bars, 100 μm. **P < .01. D, Effect of TP53TG1 upregulation on the anchorage-independent growth capacity of PANC-1 and MIA PaCa-2 cells was determined using colony formation assays. **P < .01. E, Transwell assays were carried out to determine the invasive ability of PANC-1 and MIA PaCa-2 cells after upregulation of TP53TG1. ***P < .001
and KRAS, the full-length of TP53TG1 or 3′UTR of KRAS were inserted into the pmirGLO dual luciferase reporter vector, which con- by directly binding to KRAS mRNA 3′UTR or TP53TG1 specific sites.
Further, the results also suggested that there is competition for miR-96 between KRAS and TP53TG1.
| TP53TG1 functions as a ceRNA to regulate KRAS expression by sponging miR-96
Mutated KRAS was proposed to be a hallmark of PDAC as this protein is mutated in more than 90% of PDAC cases. KRAS mutation was also found in almost all PDAC cell lines, but BxPC-3 was determined to be wild-type. 33 Knockdown of TP53TG1 in KRAS mutant 
| D ISCUSS I ON
Recent reports showed that TP53TG1 was either overexpressed or underexpressed, exerting oncogenic or tumor-suppressing functions in different tumors. [24] [25] [26] In the present study, we identified the function of TP53TG1 in PDAC by applying loss-of-function and gain-offunction approaches. We found that knockdown of TP53TG1 led to decreased proliferation, migration and invasion of PDAC cells, whereas ectopic expression of TP53TG1 promoted malignant activity. These findings suggest that TP53TG1 may play a critical role in the promotion of multiple oncogenic properties in PDAC during initial development and progression.
Results of RNA-seq (BioProject: PRJEB4337), which was carried out on tissue samples from 95 human individuals representing 27 different tissues, showed that the expression of TP53TG1 was second highest in normal colon and lowest in normal pancreas tissues ( Figure S5 ). We speculated that the different functions of TP53TG1
in gastrointestinal cancer and PDAC may be partly attributable to its tissue-specific expression pattern. However, further study is required to elucidate the multiple roles of this lncRNA in tumors.
Previous studies have shown that the mechanism of lncRNAs in human disease is associated with their cellular localization. lncRNAs located in the nucleus could interact with chromatin modifiers and specific genomic loci, whereas lncRNAs located in the cytoplasm can serve as miRNA sponges to regulate the expression of miRNA target genes through competition for shared miRNA response elements. 34 In the present study, subcellular localization analysis of TP53TG1 by RNA fluorescence in situ hybridization assay showed that TP53TG1 was mainly localized in the cytoplasm, so we hypothesized that TP53TG1 may also serve as a ceRNA. Activating mutations in the KRAS oncogene are found in a broad range of human cancers including pancreatic, colorectal, lung and urachal carcinoma, which is widely considered essential for carcinogenesis. [35] [36] [37] [38] [39] Although research shows that KRAS mutations occur in approximately 90%-95% of PDAC cases, 40 which act as a key event in the initiation and maintenance of PDAC, 41 some results further imply that KRAS overexpression is also valuable in the process of tumorigenesis.
Zeng et al 42 demonstrated that siRNA-directed KRAS silencing caused defective abilities of proliferation and invasion of pancreatic cancer cells.
Moreover, miR-217 and miR-193b were found as inhibitors in the development of PDAC by suppressing KRAS expression. In the present study, we further provide evidence that TP53TG1 can function as ceRNA to upregulate KRAS expression through competitive combination with miR-96, thus promoting PDAC cell proliferation and invasion.
Although ceRNA research is in its initial stages, accumulating data indicate that this is a new dimension of post-transcriptional gene regulation in which RNA transcripts control miRNA activity. This effect has profound implications for cancer initiation and progression.
For example, lncRNA DANCR promotes osteosarcoma development by acting as a molecular sponge of miR-335-5p and miR-1972. 43 Similarly, lncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer, acting mechanistically by upregulating ERBB4 in part through sponging miR-193a-3p. 44 Additionally, lncRNA SNHG6-003 could upregulate TAK1 expression by sequestering miR-26a/b and promoting the progression of hepatocellular carcinoma. 45 Our present study showed that ceRNA-associated KRAS modulation is involved in the carcinogenesis of PDAC.
In summary, our study identifies that lncRNA TP53TG1 is upreg- 
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